Education
About Us
Working with TipRanks
Follow Us
Revolution Medicines (RVMD)
NASDAQ:RVMD
RVMD Analyst Ratings
Strong Buy
16 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
RVMD Stock 12 Month Forecast
Average Price Target
$74.92
▲(38.48% Upside)
| Highest Price Target$85.00 | Average Price Target$74.92 | Lowest Price Target$66.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Piper Sandler
$75
Buy
38.63%
Upside
Reiterated
10/17/25
LifeSci Capital
$80
Buy
47.87%
Upside
Reiterated
10/17/25
Promising Prospects for Revolution Medicines: Buy Rating Affirmed on Daraxonrasib's CNPV Designations: Yesterday aer market close, the FDA announced that daraxonrasib has been selected as one of the first nine recipients of the new CNPV program (LINK), which is awarded to products with significant potenal to address a major naonal priority (i.e addressing a health crisis or a large unmet need, increasing affordability, etc.). This program was officially announced in June 2025 (LINK) with the goal of creang more efficient approval processes and modernize regulatory frameworks. With the CNPV designaon, daraxonrasib is expected to receive a decision within 1-2 months following NDA submission, supported by enhanced communicaons with the agency throughout the development process. Once the NDA is submied, it will be reviewed through a 1-day “tumor board style” meeng, with a muldisciplinary team of physicians and sciensts.
Raymond James
$72→$76
Buy
40.48%
Upside
Reiterated
10/17/25
Oppenheimer
$75
Buy
38.63%
Upside
Reiterated
10/17/25
Bank of America Securities
―
Buy
―
Reiterated
10/17/25
Wedbush
$77
Buy
42.33%
Upside
Reiterated
10/17/25
Barclays
$72
Buy
33.09%
Upside
Reiterated
10/17/25
Stifel Nicolaus
$85
Buy
57.12%
Upside
Initiated
10/16/25
J.P. Morgan
$71
Buy
31.24%
Upside
Reiterated
09/25/25
Truist Financial
―
Buy
―
Reiterated
09/25/25
Wells Fargo
$67→$70
Buy
29.39%
Upside
Reiterated
09/11/25
TD Cowen
―
Buy
―
Reiterated
09/11/25
Needham
$56→$66
Buy
22.00%
Upside
Reiterated
09/11/25
Leerink Partners
―
Buy
―
Reiterated
09/11/25
H.C. Wainwright
$72
Buy
33.09%
Upside
Reiterated
08/08/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Piper Sandler
$75
Buy
38.63%
Upside
Reiterated
10/17/25
LifeSci Capital
$80
Buy
47.87%
Upside
Reiterated
10/17/25
Promising Prospects for Revolution Medicines: Buy Rating Affirmed on Daraxonrasib's CNPV Designations: Yesterday aer market close, the FDA announced that daraxonrasib has been selected as one of the first nine recipients of the new CNPV program (LINK), which is awarded to products with significant potenal to address a major naonal priority (i.e addressing a health crisis or a large unmet need, increasing affordability, etc.). This program was officially announced in June 2025 (LINK) with the goal of creang more efficient approval processes and modernize regulatory frameworks. With the CNPV designaon, daraxonrasib is expected to receive a decision within 1-2 months following NDA submission, supported by enhanced communicaons with the agency throughout the development process. Once the NDA is submied, it will be reviewed through a 1-day “tumor board style” meeng, with a muldisciplinary team of physicians and sciensts.
Raymond James
$72→$76
Buy
40.48%
Upside
Reiterated
10/17/25
Oppenheimer
$75
Buy
38.63%
Upside
Reiterated
10/17/25
Bank of America Securities
―
Buy
―
Reiterated
10/17/25
Wedbush
$77
Buy
42.33%
Upside
Reiterated
10/17/25
Barclays
$72
Buy
33.09%
Upside
Reiterated
10/17/25
Stifel Nicolaus
$85
Buy
57.12%
Upside
Initiated
10/16/25
J.P. Morgan
$71
Buy
31.24%
Upside
Reiterated
09/25/25
Truist Financial
―
Buy
―
Reiterated
09/25/25
Wells Fargo
$67→$70
Buy
29.39%
Upside
Reiterated
09/11/25
TD Cowen
―
Buy
―
Reiterated
09/11/25
Needham
$56→$66
Buy
22.00%
Upside
Reiterated
09/11/25
Leerink Partners
―
Buy
―
Reiterated
09/11/25
H.C. Wainwright
$72
Buy
33.09%
Upside
Reiterated
08/08/25
Best Analysts Covering Revolution Medicines
1 Month
xxx
Success Rate
5/9 ratings generated profit
Average Return
+11.40%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 55.56% of your transactions generating a profit, with an average return of +11.40% per trade.
3 Months
xxx
Success Rate
10/14 ratings generated profit
Average Return
+10.91%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 71.43% of your transactions generating a profit, with an average return of +10.91% per trade.
1 Year
Success Rate
7/9 ratings generated profit
Average Return
+15.74%
reiterated a buy rating 2 months ago
Copying Michael Schmidt's trades and holding each position for 1 Year would result in 77.78% of your transactions generating a profit, with an average return of +15.74% per trade.
2 Years
xxx
Success Rate
13/14 ratings generated profit
Average Return
+25.82%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 92.86% of your transactions generating a profit, with an average return of +25.82% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
RVMD Analyst Recommendation Trends
Rating
Jun 25
Jul 25
Aug 25
Sep 25
Oct 25
Strong Buy
20
16
21
27
26
Buy
6
6
5
9
15
Hold
1
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
27
22
26
36
41
Each month's total comprises the sum of three months' worth of ratings.
RVMD Financial Forecast
RVMD Stock Forecast FAQ
What is RVMD’s average 12-month price target, according to analysts?
Based on analyst ratings, Revolution Medicines’s 12-month average price target is 74.92.
What is RVMD’s upside potential, based on the analysts’ average price target?
Revolution Medicines has 38.48% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is RVMD a Buy, Sell or Hold?
Revolution Medicines has a consensus rating of Strong Buy which is based on 16 buy ratings, 0 hold ratings and 0 sell ratings.
What is Revolution Medicines’s price target?
The average price target for Revolution Medicines is 74.92. This is based on 16 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $85.00 ,the lowest forecast is $66.00. The average price target represents 38.48% Increase from the current price of $54.1.
The highest analyst price target is $85.00 ,the lowest forecast is $66.00. The average price target represents 38.48% Increase from the current price of $54.1.
What do analysts say about Revolution Medicines?
Revolution Medicines’s analyst rating consensus is a Strong Buy. This is based on the ratings of 16 Wall Streets Analysts.
How can I buy shares of RVMD?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.